Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
Sung Won Chung, Hye‐Sung Moon, Hyun‐Jae Shin, et al.
Hepatology (2024) Vol. 80, Iss. 3, pp. 633-648
Closed Access | Times Cited: 12

Showing 12 citing articles:

Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Byungyoon Yun, Juyeon Oh, Heejoo Park, et al.
Liver International (2025) Vol. 45, Iss. 5
Closed Access | Times Cited: 2
Preventing the progression of cirrhosis to decompensation and death
Càndid Villanueva, Dhiraj Tripathi, Jaime Bosch
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 1
Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD
Giovanni Targher, Herbert Tilg, Luca Valenti
Liver International (2025) Vol. 45, Iss. 4
Open Access | Times Cited: 1
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 6
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan
Takumi Kawaguchi, Yoshiyuki Fujishima, Daisuke Wakasugi, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 12, pp. 1120-1132
Open Access | Times Cited: 6
Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges
Shan Luo, Ming‐Hua Zheng, Vincent Wai‐Sun Wong, et al.
eGastroenterology (2024) Vol. 2, Iss. 4, pp. e100114-e100114
Open Access | Times Cited: 4
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
Yu Shi, Nicholas Chien, Ashley Fong, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, et al.
Cells (2025) Vol. 14, Iss. 6, pp. 428-428
Open Access
Plasma protein levels and hepatocellular carcinoma: a Mendelian randomization study with drug screening implications
Longhui Xie, Dekun Song, Jianwei Lan, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health
Haozhang Huang, Huangtao Ruan, Xiaozhao Lu, et al.
Metabolism (2025), pp. 156276-156276
Closed Access
Hematological traits in sodium-glucose cotransporter-2 efficacy: mediators or confounders ?
Yuanhao Wei, Lanlan Chen, Kun Zhao
Hepatology (2024)
Closed Access
Role of gliflozins on hepatocellular carcinoma progression: a systematic synthesis of preclinical and clinical evidence
Livia Basile, Rossella Cannarella, Paolo Magni, et al.
Expert Opinion on Drug Safety (2024), pp. 1-14
Closed Access
Page 1

Scroll to top